In early February 2025, NIH announced a policy change capping indirect cost reimbursement at 15% of total direct costs. This abrupt decision now threatens the future of research, training, and scientific infrastructure at research institutions nationwide.
In response, Tom Maniatis, PhD, Evnin Family Scientific Director and CEO of the New York Genome Center, has penned an article published today in Cell Press. In the article, Dr. Maniatis discusses NIH’s role in positioning the United States as a leader in biomedical research and warns that the cuts will weaken the U.S. biomedical ecosystem.
If you’d like to take additional action, we ask that you sign this petition and circulate it within your network.
